Device/Diagnostics Quarterly Deal-Making Statistics, Q1 2018
A look at the financing, M&A and alliance activity in January-March 2018
Executive Summary
Device fundraising in the first quarter totaled $7.6 billion, thanks to Siemens Healthineers $5.2 billion IPO, which accounted for more than two-thirds of the total. Q1 M&A activity reached $6.7 billion, a significant rise from Q4's $3.9 billion. Similarly, aggregate first quarter diagnostics financings (at $1.5 billion) and M&As (at $543 million) also experienced substantial increases over the previous quarter.
You may also be interested in...
Varian Stands Firm Against Rival Bid For SirTex; What Next If It All Falls Down?
Varian Medical Systems' proposed $1.3bn deal to acquire SirTex Medical is officially in jeopardy after China's CDH Investments formalized its rival bid to snatch away the Australian interventional oncology firm. Should the deal fall through, what would Varian's next steps be?
'Watch This Space' Roche Execs Say, Outlining RWE Rationale For Flatiron Buy
Buying Flatiron Health offers research-quality electronic medical records data which will help gain access to patients and help in the drug development and reimbursement process, Roche exes say.
Boston Scientific Scores March M&A Double Whammy With NxThera
In its second acquisition deal this month, Boston Scientific has agreed to pay up to $406m for NxThera, maker of the Rezῡm system for treating benign prostatic hyperplasia.